Aurinia Pharmaceuticals (AUPH): First Take On CEO Transition - HC Wainwright

February 7, 2017 7:33 AM EST Send to a Friend
H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) after the compnay's Board ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login